세계의 중증 급성 호흡기 증후군 치료 시장 보고서(2025년)

Severe acute respiratory syndrome (SARS) is a severe type of pneumonia caused by an airborne virus that can be transmitted through tiny droplets of saliva. This previously unidentified virus belongs to the Coronaviridae family and is known as SARS-associated COVID-19 (SARS-CoV). The treatment for severe acute respiratory syndrome (SARS) involves medical interventions and supportive measures aimed at managing the symptoms and complications of this viral respiratory illness.

The primary classes of drugs used in the treatment of severe acute respiratory syndrome include antibiotics, antivirals, corticosteroids, monoclonal antibodies, and others. Antibiotics are a class of medications used to treat bacterial infections. They function by either killing bacteria or inhibiting their growth, depending on the specific type of antibiotic. In the context of severe acute respiratory syndrome caused by SARS-CoV and SARS-CoV-2, these antibiotics are administered orally and intravenously. They are distributed through various channels, including hospital pharmacies and retail pharmacies, among others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The severe acute respiratory syndrome treatment market research report is one of a series of new reports from The Business Research Company that provides severe acute respiratory-syndrome treatment market statistics, including severe acute respiratory-syndrome treatment industry global market size, regional shares, competitors with a severe acute respiratory syndrome treatment market share, detailed severe acute respiratory-syndrome treatment market segments, market trends and opportunities and any further data you may need to thrive in the severe acute respiratory-syndrome treatment industry. This severe acute respiratory-syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The severe acute respiratory-syndrome treatment market size has grown rapidly in recent years. It will grow from $3.45 billion in 2024 to $3.94 billion in 2025 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to global outbreak response, antiviral drug development, vaccine development, public health preparedness.

The severe acute respiratory-syndrome treatment market size is expected to see rapid growth in the next few years. It will grow to $7.08 billion in 2029 at a compound annual growth rate (CAGR) of 15.8%. The growth in the forecast period can be attributed to broad-spectrum antivirals, emerging therapeutics, vaccine advancements, pandemic preparedness. Major trends in the forecast period include rna-targeted therapies, ai in drug discovery, global collaborations, public health education.

The forecast of 15.8% growth over the next five years remains unchanged from the previous projection for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. pandemic preparedness by increasing costs for high-flow nasal cannula systems and antiviral medications imported from Switzerland and Japan, potentially compromising emergency respiratory care and raising critical care unit expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of respiratory diseases is expected to drive the growth of the severe acute respiratory syndrome (SARS) treatment market in the coming years. Respiratory diseases encompass a range of conditions that affect the respiratory system, which is responsible for breathing and facilitating gas exchange between the body and the environment. Treatments for severe acute respiratory syndrome aim to alleviate symptoms, prevent respiratory failure, reduce inflammation, and maintain oxygen levels. For example, in November 2023, the National Asthma Council, an Australia-based non-profit organization focused on asthma care, reported 467 asthma-related deaths in 2022, including 299 females and 168 males. This marked an increase from the 355 deaths recorded in 2021. Therefore, the rising incidence of respiratory diseases is fueling the growth of the severe acute respiratory syndrome treatment market.

The progressive surge in investments in research and development is poised to be a catalyst for the growth of the severe acute respiratory syndrome treatment market in the near future. These investments in research and development, often abbreviated as R&D, pertain to the allocation of financial resources and human expertise by organizations, governments, or entities with the aim of conducting systematic and innovative investigations and initiatives, with the goal of unearthing fresh knowledge. Augmented R&D investments play a pivotal role in advancing the array of available treatment options for severe acute respiratory syndromes, including conditions like SARS and COVID-19. Such investments contribute to the formulation of effective drugs, vaccines, diagnostic tools, and therapeutic strategies, ultimately enhancing patient outcomes and reinforcing global health preparedness. Notably, in August 2023, the United States Department of Health and Human Services, the executive branch department of the U.S. federal government, disclosed that the U.S. Department of Health and Human Services (HHS), in collaboration with the Administration for Strategic Preparedness and Response (ASPR), had allocated over $1.4 billion for Project NextGen. This initiative aims to support the development of the next generation of COVID-19 vaccines and treatments. Consequently, the increasing investments in research and development are the pivotal driving force behind the growth of the severe acute respiratory syndrome treatment market.

Leading companies actively participating in the severe acute respiratory syndrome treatment market are at the forefront of introducing innovative techniques, with a notable example being multiplexed real-time PCR. Multiplexed real-time PCR is a molecular biology technology that facilitates the simultaneous amplification and detection of multiple DNA or RNA targets in a single procedure. A case in point is the product launched by TransGen Biotech Co. Ltd., a Beijing-based manufacturer and researcher of molecular and cellular biology products, in July 2022. They introduced the Trans-SARS-CoV-2, Influenza A and B, and Respiratory Syncytial Virus Assay. This groundbreaking assay is designed as a multiplexed real-time PCR (polymerase chain reaction) assay, capable of detecting and distinguishing severe acute respiratory syndrome COVID-19 2 (SARS-CoV-2), Influenza A, Influenza B, and respiratory syncytial virus (RSV) in a single specimen. This innovative tool plays a crucial role in the diagnosis and treatment of severe acute respiratory syndromes, including COVID-19, influenza, and RSV, thus aiding in guiding treatment decisions and preventing the spread of these diseases.

In March 2022, AbbVie Inc., a U.S.-based pharmaceutical company, established a collaboration with Scripps Research, an independent, non-profit biomedical research and drug discovery institute also based in the United States. This strategic partnership is geared toward the development of cutting-edge direct-acting antiviral therapies designed for the treatment of COVID-19. The collaboration aims to pioneer innovative solutions for combatting the virus.

Major companies operating in the severe acute respiratory-syndrome treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck And Co Inc., Novartis AG, Bristol Myers Squib company, GlaxoSmithKline PLC, AstraZeneca PLC, Sanofi SA, Eli Lilly And Company, Gilead Sciences Inc., Amgen Inc., Johnson And Johnson Private Limited, Moderna Inc., Regeneron Pharmaceuticals Inc., Hetero labs Ltd., Alexion Pharmaceuticals Inc., Cadila healthcare Ltd., Genentech Inc., Cipla Ltd., Biogen Inc., Vir Biotechnology Inc., Swedish Orphan Biovitrum AB, Dynavax Technologies Corporation, ViiV Healthcare Limited, Panacea Biotec Limited, CureVac N.V., CN Bio Innovations Ltd., Inovio Pharmaceuticals Inc., Chimerix Inc.

North America was the largest region in the severe acute respiratory syndrome treatment market in 2024. Western Europe is expected to be the fastest-growing region in the forecast period. The regions covered in severe acute respiratory syndrome treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the severe acute respiratory syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The severe acute respiratory syndrome treatment market consists of revenues earned by entities by providing services such as respiratory therapy, oxygen therapy, ventilation, intensive care, isolation and infection control, fluid and electrolyte management and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The severe acute respiratory syndrome treatment market also includes sales of azithromycin, immunomodulators, vaccines, ribavirin, ritonavir, remdesivir, methylprednisolone, prednisolone, dexamethasone and interferon. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Severe Acute Respiratory-Syndrome Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on severe acute respiratory-syndrome treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for severe acute respiratory-syndrome treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The severe acute respiratory-syndrome treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Antibiotics; Antiviral; Corticosteroids; Monoclonal Antibodies; Other Drug Classes
• 2) By Route Of Administration: Oral; Intravenous
• 3) By Indication: Severe Acute Respiratory Syndrome COVID-19 (SARS-CoV); Severe Acute Respiratory Syndrome COVID-19 2 (SARS-CoV-2)
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Antibiotics: Broad-Spectrum Antibiotics; Narrow-Spectrum Antibiotics
• 2) By Antiviral: Nucleoside Analogs; Protease Inhibitors
• 3) By Corticosteroids: Systemic Corticosteroids; Inhaled Corticosteroids
• 4) By Monoclonal Antibodies: Neutralizing Antibodies; Non-Neutralizing Antibodies
• 5) By Other Drug Classes: Immunomodulators; Supportive Medications
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Merck And Co Inc.; Novartis AG; Bristol Myers Squib company; GlaxoSmithKline plc; AstraZeneca plc; Sanofi SA; Eli Lilly And Company; Gilead Sciences Inc.; Amgen Inc.; Johnson And Johnson Private Limited; Moderna Inc.; Regeneron Pharmaceuticals Inc.; Hetero labs Ltd.; Alexion Pharmaceuticals Inc.; Cadila healthcare Ltd.; Genentech Inc.; Cipla Ltd.; Biogen Inc.; Vir Biotechnology Inc.; Swedish Orphan Biovitrum AB; Dynavax Technologies Corporation; ViiV Healthcare Limited; Panacea Biotec Limited; CureVac N.V.; CN Bio Innovations Ltd.; Inovio Pharmaceuticals Inc.; Chimerix Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Severe Acute Respiratory-Syndrome Treatment Market Characteristics

3. Severe Acute Respiratory-Syndrome Treatment Market Trends And Strategies

4. Severe Acute Respiratory-Syndrome Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Severe Acute Respiratory-Syndrome Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Severe Acute Respiratory-Syndrome Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Severe Acute Respiratory-Syndrome Treatment Market Growth Rate Analysis
• 5.4. Global Severe Acute Respiratory-Syndrome Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Severe Acute Respiratory-Syndrome Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Severe Acute Respiratory-Syndrome Treatment Total Addressable Market (TAM)

6. Severe Acute Respiratory-Syndrome Treatment Market Segmentation

• 6.1. Global Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotics
• Antiviral
• Corticosteroids
• Monoclonal Antibodies
• Other Drug Classes
• 6.2. Global Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• 6.3. Global Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Severe Acute Respiratory Syndrome COVID-19 (SARS-CoV)
• Severe Acute Respiratory Syndrome COVID-19 2 (SARS-CoV-2)
• 6.4. Global Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels
• 6.5. Global Severe Acute Respiratory-Syndrome Treatment Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Broad-Spectrum Antibiotics
• Narrow-Spectrum Antibiotics
• 6.6. Global Severe Acute Respiratory-Syndrome Treatment Market, Sub-Segmentation Of Antiviral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nucleoside Analogs
• Protease Inhibitors
• 6.7. Global Severe Acute Respiratory-Syndrome Treatment Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Systemic Corticosteroids
• Inhaled Corticosteroids
• 6.8. Global Severe Acute Respiratory-Syndrome Treatment Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Neutralizing Antibodies
• Non-Neutralizing Antibodies
• 6.9. Global Severe Acute Respiratory-Syndrome Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunomodulators
• Supportive Medications

7. Severe Acute Respiratory-Syndrome Treatment Market Regional And Country Analysis

• 7.1. Global Severe Acute Respiratory-Syndrome Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Severe Acute Respiratory-Syndrome Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Severe Acute Respiratory-Syndrome Treatment Market

• 8.1. Asia-Pacific Severe Acute Respiratory-Syndrome Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Severe Acute Respiratory-Syndrome Treatment Market

• 9.1. China Severe Acute Respiratory-Syndrome Treatment Market Overview
• 9.2. China Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Severe Acute Respiratory-Syndrome Treatment Market

• 10.1. India Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Severe Acute Respiratory-Syndrome Treatment Market

• 11.1. Japan Severe Acute Respiratory-Syndrome Treatment Market Overview
• 11.2. Japan Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Severe Acute Respiratory-Syndrome Treatment Market

• 12.1. Australia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Severe Acute Respiratory-Syndrome Treatment Market

• 13.1. Indonesia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Severe Acute Respiratory-Syndrome Treatment Market

• 14.1. South Korea Severe Acute Respiratory-Syndrome Treatment Market Overview
• 14.2. South Korea Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Severe Acute Respiratory-Syndrome Treatment Market

• 15.1. Western Europe Severe Acute Respiratory-Syndrome Treatment Market Overview
• 15.2. Western Europe Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Severe Acute Respiratory-Syndrome Treatment Market

• 16.1. UK Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Severe Acute Respiratory-Syndrome Treatment Market

• 17.1. Germany Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Severe Acute Respiratory-Syndrome Treatment Market

• 18.1. France Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Severe Acute Respiratory-Syndrome Treatment Market

• 19.1. Italy Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Severe Acute Respiratory-Syndrome Treatment Market

• 20.1. Spain Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Severe Acute Respiratory-Syndrome Treatment Market

• 21.1. Eastern Europe Severe Acute Respiratory-Syndrome Treatment Market Overview
• 21.2. Eastern Europe Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Severe Acute Respiratory-Syndrome Treatment Market

• 22.1. Russia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Severe Acute Respiratory-Syndrome Treatment Market

• 23.1. North America Severe Acute Respiratory-Syndrome Treatment Market Overview
• 23.2. North America Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Severe Acute Respiratory-Syndrome Treatment Market

• 24.1. USA Severe Acute Respiratory-Syndrome Treatment Market Overview
• 24.2. USA Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Severe Acute Respiratory-Syndrome Treatment Market

• 25.1. Canada Severe Acute Respiratory-Syndrome Treatment Market Overview
• 25.2. Canada Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Severe Acute Respiratory-Syndrome Treatment Market

• 26.1. South America Severe Acute Respiratory-Syndrome Treatment Market Overview
• 26.2. South America Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Severe Acute Respiratory-Syndrome Treatment Market

• 27.1. Brazil Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Severe Acute Respiratory-Syndrome Treatment Market

• 28.1. Middle East Severe Acute Respiratory-Syndrome Treatment Market Overview
• 28.2. Middle East Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Severe Acute Respiratory-Syndrome Treatment Market

• 29.1. Africa Severe Acute Respiratory-Syndrome Treatment Market Overview
• 29.2. Africa Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Severe Acute Respiratory-Syndrome Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Severe Acute Respiratory-Syndrome Treatment Market Competitive Landscape And Company Profiles

• 30.1. Severe Acute Respiratory-Syndrome Treatment Market Competitive Landscape
• 30.2. Severe Acute Respiratory-Syndrome Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck And Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Severe Acute Respiratory-Syndrome Treatment Market Other Major And Innovative Companies

• 31.1. Bristol Myers Squib company
• 31.2. GlaxoSmithKline plc
• 31.3. AstraZeneca plc
• 31.4. Sanofi SA
• 31.5. Eli Lilly And Company
• 31.6. Gilead Sciences Inc.
• 31.7. Amgen Inc.
• 31.8. Johnson And Johnson Private Limited
• 31.9. Moderna Inc.
• 31.10. Regeneron Pharmaceuticals Inc.
• 31.11. Hetero labs Ltd.
• 31.12. Alexion Pharmaceuticals Inc.
• 31.13. Cadila healthcare Ltd.
• 31.14. Genentech Inc.
• 31.15. Cipla Ltd.

32. Global Severe Acute Respiratory-Syndrome Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Severe Acute Respiratory-Syndrome Treatment Market

34. Recent Developments In The Severe Acute Respiratory-Syndrome Treatment Market

35. Severe Acute Respiratory-Syndrome Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Severe Acute Respiratory-Syndrome Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Severe Acute Respiratory-Syndrome Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Severe Acute Respiratory-Syndrome Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer